| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL36R |
| Uniprot No | Q9HB29 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-575aa |
| 氨基酸序列 | MWSLLLCGLSIALPLSVTADGCKDIFMKNEILSASQPFAFNCTFPPITSGEVSVTWYKNSSKIPVSKIIQSRIHQDETWILFLPMEWGDSGVYQCVIKGRDSCHRIHVNLTVFEKHWCDTSIGGLPNLSDEYKQILHLGKDDSLTCHLHFPKSCVLGPIKWYKDCNEIKGERFTVLETRLLVSNVSAEDRGNYACQAILTHSGKQYEVLNGITVSITERAGYGGSVPKIIYPKNHSIEVQLGTTLIVDCNVTDTKDNTNLRCWRVNNTLVDDYYDESKRIREGVETHVSFREHNLYTVNITFLEVKMEDYGLPFMCHAGVSTAYIILQLPAPDFRAYLIGGLIALVAVAVSVVYIYNIFKIDIVLWYRSAFHSTETIVDGKLYDAYVLYPKPHKESQRHAVDALVLNILPEVLERQCGYKLFIFGRDEFPGQAVANVIDENVKLCRRLIVIVVPESLGFGLLKNLSEEQIAVYSALIQDGMKVILIELEKIEDYTVMPESIQYIKQKHGAIRWHGDFTEQSQCMKTKFWKTVRYHMPPRRCRPFPPVQLLQHTPCYRTAGPELGSRRKKCTLTTG |
| 预测分子量 | 65,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与IL-36R重组蛋白相关的文献示例(注：内容基于公开研究概括，部分信息可能需要通过学术数据库验证)：
---
1. **标题**: *"IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform inflammation"*
**作者**: Tortola L. et al.
**摘要**: 研究通过重组IL-36R蛋白及拮抗性抗体，在小鼠银屑病模型中验证了阻断IL-36R信号可显著减轻皮肤炎症和角质形成细胞过度增殖，为靶向治疗提供依据。
2. **标题**: *"Therapeutic targeting of IL-36 signaling in generalized pustular psoriasis: a phase I clinical trial"*
**作者**: Bachelez H. et al.
**摘要**: 报道抗IL-36R单抗(如Imsidolimab)的I期临床试验结果，证明其通过结合重组IL-36R蛋白阻断下游促炎因子释放，有效缓解泛发性脓疱型银屑病症状。
3. **标题**: *"Structural characterization of IL-36 receptor ligand interactions and implications for drug design"*
**作者**: Günther S. et al.
**摘要**: 利用重组IL-36R蛋白进行晶体结构分析，揭示了IL-36配体与受体的结合机制，为开发小分子抑制剂或抗体药物提供结构生物学基础。
---
如需具体文献全文，建议通过PubMed或Sci-Hub输入标题检索。部分研究可能涉及企业合作(如AnaptysBio/勃林格殷格翰)，可通过其官网获取临床试验简报。
Interleukin-36 receptor (IL-36R), also known as IL1RL2. is a key component of the interleukin-1 (IL-1) cytokine receptor family, primarily involved in inflammatory and immune responses. It binds to IL-36 agonists (IL-36α, IL-36β, IL-36γ) to form a signaling complex with the IL-1 receptor accessory protein (IL-1RAcP), activating downstream pathways such as NF-κB and MAPK. This triggers proinflammatory cytokine production, immune cell recruitment, and tissue remodeling. Dysregulated IL-36R signaling is implicated in psoriasis, atopic dermatitis, rheumatoid arthritis, and inflammatory bowel disease, making it a therapeutic target.
Recombinant IL-36R proteins are engineered using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and bioactivity. These proteins typically include the extracellular domain, enabling studies on receptor-ligand interactions, signaling mechanisms, and inhibitor screening. Purification via affinity chromatography yields high-purity products for structural analysis, in vitro binding assays, and preclinical models.
In drug development, IL-36R antagonists like spesolimab (approved for generalized pustular psoriasis) have demonstrated efficacy by blocking pathogenic signaling. Recombinant IL-36R also aids in biomarker discovery and personalized therapeutic strategies. Its role in bridging innate/adaptive immunity underscores its relevance in autoimmune and hyperinflammatory conditions, driving ongoing research into targeted modulators.
×
